Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Celldex Therapeutics Inc. maintains a company patent portfolio within the Biotechnology & Pharmaceuticals technology area. The portfolio currently features 1 pending office action, which is being handled by 1 distinct examiner. This indicates a concentrated prosecution effort where all active matters are localized within 1 distinct art unit. The focus within the Biotechnology & Pharmaceuticals sector suggests that the company's current legal challenges are confined to a specific subset of their technology. Practitioners should note that this concentration allows for a very specific technical dialogue with the patent office.
The busiest examiner for this portfolio is HADDAD, MAHER M, who is responsible for 1 pending office action. Because this examiner manages the entirety of the company's current workload, the prosecution strategy is currently limited to a single point of contact. This centralization means that the outcome of the entire pending portfolio rests on the decisions of this individual. There are no other active office actions to compare against, which simplifies the monitoring process but increases the impact of the examiner's perspective on the 1 pending office action.
The alignment of the distinct examiner across the art unit suggests a narrow technical focus for the pending matters. This concentration ensures that the workload is distributed such that the busiest examiner handles the only pending action. This represents the full scope of the company's current interactions with the patent office. For a practitioner, the primary task is to establish a consistent and persuasive relationship with HADDAD, MAHER M to advance the portfolio through the current prosecution cycle.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HADDAD, MAHER M | 1 | 50.6% | +53.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18634562 | TREATMENT OF EOSINOPHIL OR MAST CELL RELATED DISORDERS | HADDAD, MAHER M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18634562 | TREATMENT OF EOSINOPHIL OR MAST CELL RELATED DISORDERS | HADDAD, MAHER M | — |
| Art Unit | Apps |
|---|---|
| 1641 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18634562 | TREATMENT OF EOSINOPHIL OR MAST CELL RELATED DISORDERS | HADDAD, MAHER M | 1641 | §102§112Other | Non-Final OA | — | Pending | Apr 12, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCelldex Therapeutics Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Maher M Haddad has the most, with 1 of Celldex Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.